The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough designation.
AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. The green light for ...
Asthma is a serious medical condition that causes inflammation and constriction of the airways. If left untreated, it can affect your quality of life. A severe asthma attack can sometimes be fatal.
The study, published in Science Translational Medicine on Jan. 15, 2025, sheds light on the complex mechanisms behind severe asthma and opens new avenues for potential treatments. Asthma is a ...